^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:gumarontinib (SCC244) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    ecancer
    Title:

    NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation

    Published date:
    03/08/2023
    Excerpt:
    Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation got conditional approval on March 8, 2023, by the National Medical Products Administration (NMPA) of China.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Safety and Anti-tumor Activity of SCC244

    Excerpt:
    ...In Phase Ia, histologically confirmed NSCLC (including sarcomatoid carcinoma) with c-Met alterations defined as c-Met gene amplification ≥ 5 copies or c-Met protein overexpression (IHC 3+) or c-Met exon 14 skipping mutation....
    Trial ID:
    NCT03466268